Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corp ADR (NQ: LEGN )

55.90 -1.01 (-1.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 786,690
Open 58.90
Bid (Size) 55.89 (4)
Ask (Size) 56.03 (15)
Prev. Close 56.91
Today's Range 55.00 - 58.90
52wk Range 38.60 - 72.38
Shares Outstanding 308,456,852
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
LEGN Stock Earnings: Legend Biotech Beats EPS, Beats Revenue for Q2 2024
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire

Performance

YTD
-5.41%
-5.41%
1 Month
+15.26%
+15.26%
3 Month
+30.09%
+30.09%
6 Month
-7.57%
-7.57%
1 Year
-21.58%
-21.58%

More News

Read More
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
From Legend Biotech USA Inc.
Via GlobeNewswire
Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
Via Benzinga
The Latest Analyst Ratings For Legend Biotech
Via Benzinga
Assessing Legend Biotech: Insights From 15 Financial Analysts
Via Benzinga
Unveiling 18 Analyst Insights On Legend Biotech
Via Benzinga
Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
Via Benzinga
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
From Legend Biotech USA Inc.
Via GlobeNewswire
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
Via Benzinga
Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal
Via Talk Markets
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
Via Benzinga
CPI Data Sparks Rally in Biotech Stocks
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
Via Benzinga
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Via Benzinga
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Via Benzinga
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
From Legend Biotech
Via Business Wire
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
From Legend Biotech Corporation
Via Business Wire
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
Via Talk Markets
LEGN Stock Earnings: Legend Biotech Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.